Ketamine treatment represents a groundbreaking advancement in mental health care, offering a new pathway towards mental wellness and improved quality of life with minimal risk of adverse effects. Ketamine effectively assists individuals unresponsive to conventional treatments (Griffiths et al., 2021). Its effectiveness in treating various mental health conditions, including chronic PTSD (Feder et al., 2014, 2021), treatment-resistant depression (Feifel et al., 2017), and substance use disorders (Jones et al., 2018), has been extensively documented. Ketamine’s rapid onset of action is remarkable, with some people experiencing mood improvements within a mere 24 hours (Feifel et al., 2017). Repeated ketamine administrations lead to cumulative antidepressant effects, ensuring sustained improvement over time (Phillips et al., 2019). Ketamine’s therapeutic benefit stems from its modulation of N-methyl-D-aspartate receptors within the brain’s glutamatergic system. By fostering neural plasticity and connectivity, ketamine can recalibrate the neural networks disrupted in mood disorders such as depression, resulting in rapid improvements in mood and cognitive functions (Xu et al., 2022)..

A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder

May 15, 20240

Posttraumatic stress disorder (PTSD) is a chronic and disabling disorder, for which available pharmacotherapies have limited efficacy. The authors’ previous proof-of-concept randomized controlled trial of single-dose intravenous ketamine infusion in individuals with PTSD showed significant and rapid PTSD symptom reduction 24 hours postinfusion. The present study is the first randomized controlled trial to test the efficacy and safety of repeated intravenous ketamine infusions for the treatment of chronic PTSD.

Leave a Reply

Your email address will not be published. Required fields are marked *